GT Biopharma annual operating margin
2010
2011
2012
2013
2014
2015
GT Biopharma's operating margin was −33,062.96% for fiscal 2015.
View full GT Biopharma company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2015 | 2015-12-31 | −33,062.96% | −29135.09 pp |
| 2014 | 2014-12-31 | −3,927.87% | −3712.38 pp |
| 2013 | 2013-12-31 | −215.49% | +812.00 pp |
| 2012 | 2012-12-31 | −1,027.49% | +14080.21 pp |
| 2011 | 2011-12-31 | −15,107.69% | +7592.31 pp |
| 2010 | 2010-12-31 | −22,700.00% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2015 | 2015-06-30 | −7,155.00% | −6739.00 pp |
| Q1 2015 | 2015-03-31 | −25,871.43% | −25794.93 pp |
| Q4 2014 | 2014-12-31 | −4,975.76% | −4899.25 pp |
| Q3 2014 | 2014-09-30 | −18,300.00% | −17905.68 pp |
| Q2 2014 | 2014-06-30 | −416.00% | −80.55 pp |
| Q3 2013 | 2013-09-30 | −76.50% | +1048.50 pp |
| Q2 2013 | 2013-06-30 | −76.50% | +102923.50 pp |
| Q1 2013 | 2013-03-31 | −394.32% | +39205.68 pp |
| Q4 2012 | 2012-12-31 | −335.45% | +34597.88 pp |
| Q3 2012 | 2012-09-30 | −1,125.00% | +25925.00 pp |
| Q2 2012 | 2012-06-30 | −103,000.00% | −54900.00 pp |
| Q1 2012 | 2012-03-31 | −39,600.00% | −30310.00 pp |
| Q4 2011 | 2011-12-31 | −34,933.33% | — |
| Q3 2011 | 2011-09-30 | −27,050.00% | — |
| Q2 2011 | 2011-06-30 | −48,100.00% | — |
| Q1 2011 | 2011-03-31 | −9,290.00% | — |
Over the last five reported fiscal years, GT Biopharma's operating margin decreased from −22,700.00% to −33,062.96%, a change of −10362.96 percentage points. The latest reported quarter, Q2 2015, shows −7,155.00%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review GT Biopharma filings at SEC.gov ↗